BRCA1 and neoplasm: Inhibition of KLF4 could efficiently block both DNA damage response and HR in BRCA1‐proficient, TNBC tumors that, in turn, generates synthetic lethality for BRCA1‐proficient TNBC tumor cells in combination with blocking PARP function.